ERBB2 and breast carcinoma: The efficacy and safety of T-DM1 is being investigated in combination with endocrine therapy (with tamoxifen in premenopausal women and aromatase inhibitor in postmenopausal women) as neoadjuvant treatment of HER2-positive and hormone receptor-positive operable breast cancer (NCT01745965).